Previous News
2016
Immune Design
December 5, 2016 - Immune Design Provides Update from Two Discovery Platforms: DC-tropic ZVex and G100
Immune Design
November 11, 2016 - Immune Design Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Science 37
October 18, 2016 - Science 37 Secures $31M Series B Funding to Expand Clinical Trial Access to Anyone, Anywhere, Anytime
Immune Design
September 28, 2016 -Immune Design Announces Advancement of First GLAAS™-based Allergy Program into Clinical Development
Ovid Therapeutics
September 8, 2016 - Ovid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for the Treatment of Patients with Angelman Syndrome
Yumanity Therapeutics
June 22, 2016 - Yumanity Therapeutics and the New York Stem Cell Foundation Research Institute Announce Discovery Collaboration
Immune Design
June 8, 2016 - Immune Design Releases New PFS, OS and TME Data from Trials of Three Immuno-Oncology Product Candidates
Immune Design
May 10, 2016 - Immune Design Reports First Quarter 2016 Financial Results and Provides Corporate Update
Immune Design
May 9, 2016 - Immune Design and Gritstone Oncology Announce Clinical Collaboration for Neoantigen Cancer Immunotherapy.
Immune Design
April 20, 2016 - Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches
ImmuneXcite
March 30, 2016 - ImmuneXcite Closes $8.6M Financing, Adds Three Industry Veterans to Company Leadership
Immune Design
March 10, 2016 - Immune Design Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
Immune Design
March 4, 2016 - Immune Design's GLAAS™ Platform Shown to Modulate the Allergic Immune Response
Proteostasis Therapeutics
February 11, 2016 - Proteostasis Therapeutics, Inc. Announces Pricing of Initial Public Offering
Yumanity Therapeutics
February 10, 2016 - Yumanity Therapeutics Closes $45 Million Series A Financing
Immune Design
February 9, 2016 - Immune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-oncology Product Candidates
Proteostasis Therapeutics
February 1, 2016 - Proteostasis Therapeutics Receives FDA Fast Track Designation for PTI-428 in Patients with Cystic Fibrosis
Unum Therapeutics
January 26, 2016 - Unum Therapeutics Moves to New Headquarters in Cambridge, MA as it continues to Expand and Advance its Cellular Immunotherapy Pipeline
Immune Design
January 8, 2016 - Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305
2015
Navitor Pharmaceuticals
December 18, 2015 - Navitor Pharmaceuticals Announces $33M Series B Financing
Proteostasis Therapeutics
December 11, 2015 - Proteostasis Therapeutics Inc. announces management changes to strengthen Research and Development Organization
Immune Design
December 7, 2015 - Immune Design Highlights G100 Preclinical Data Demonstrating Direct and Abscopal Tumor Regression, Long-Term Response and Synergy With Checkpoint Blockade
Ovid Therapeutics
November 23, 2015 - Ovid Therapeutics Announces Election of Bart Friedman to Its Board of Directors
Proteostasis Therapeutics
November 20, 2015 - Proteostasis Therapeutics, Inc. Demonstrates Therapeutic Potential of a Proprietary Triple Combination Therapy for the Treatment of Cystic Fibrosis that Restores Activity of Mutant F508del CFTR protein to 80% of Normal
Immune Design
November 12, 2015 - Immune Design Reports Third Quarter 2015 Financial Results
Immune Design
November 11, 2015 - Immune Design Announces Start of Ramdomized Phase 2 Cancer Immunotherapy Combination Trial in Patients With Soft Tissue Sarcoma
Immune Design
November 3, 2015 - Immune Design Presents Preclinical Data on G100 and ZVex(TM) in Combination With Check Point Inhibitors at the 2015 Society for Immunotherapy of Cancer Annual Meeting
View PDF 
Immune Design
October 29, 2015 - MEDI7510 for Respiratory Syncytial Virus Advances to Phase 2 Leverages Immune Design's GLAAS(TM) Discovery Platform
View PDF
Unum Therapeutics
October 21, 2015 - Unum Therapeutics Expands Leadership Team by Appointing Dr. Michael J. Vasconcelles as Chief Medical Officer
View PDF
Proteostasis Therapeutics
October 8, 2015 - Proteostasis Therapeutics, Inc. Presents Preclinical Data for Its CFTR Amplifier Program at the 29th Annual North American Cystic Fibrosis Conference
View PDF
Ovid Therapeutics
October 8, 2015 - Ovid Therapeutics Appoints Dr. Jerome B. Zeldis to Its Scientific Advisory Board
View PDF
Ovid Therapeutics
September 30, 2015 - Ovid Therapeutics Appoints Dr. Karen Bernstein to its Board of Directors
View PDF
Proteostasis Therapeutics
September 8, 2015 - Proteostasis Therapeutics, Inc. Raises $37 Million in Crossover Financing
View PDF
Selecta Biosciences
September 8, 2015 - Selecta Announces $38 Million Series E Equity Financing
View PDF
Immune Design
August 12, 2015 - Immune Design Reports Second Quarter 2015 Financial Results
View PDF
Immune Design
August 12, 2015 - Immune Design Announces Phase 2 Cancer Immunotherapy Trial Collaboration
View PDF
Ovid Therapeutics
August 11, 2015 - Ovid Therapeutics Completes Oversubscribed $75 Million Series B Financing
View PDF
Immune Design
August 10, 2015 - Immune Design and Merk to Collaborate on Combination Trials of Two Immune Design Immunotherapies With Merck's KEYTRUDA for Non-Hodgkin's Lymphoma and Melanoma
View PDF
Fate Therapeutics
August 5, 2015 - Fate Therapeutics Reports Second Quarter 2015 Financial Results
View PDF
KaloBios
July 29, 2015 - KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia
View PDF
GlycoMimetics
June 23, 2015 - GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel
View PDF
Unum Therapeutics
June 11, 2015 - Unum Therapeutics Announces $65 Million Series B Financing Round
View PDF
Unum Therapeutics
June 8, 2015 - Seattle Genetics and Unum Therapeutics Enters Into Strategic Cancer Immunotherapy Collaboration
View PDF
Fate Therapeutics
June 5, 2015 - Fate Therapeutics Enters Into Sponsored Research Agreement With Boston Children's Hospital to Develop Immunoregulatory Cell Therapy for Treatment of Autoimmune Diseases
View PDF
Fate Therapeutics
May 20, 2015 - Fate Therapeutics Announces Pricing of Public Offering of Common Stock
View PDF
Fate Therapeutics
May 18, 2015 - Fate Therapeutics Announces Proposed Public Offering of Common Stock
View PDF
Immune Design
May 13, 2015 - Immune Design Announces Positive Data from Three Phase 1 Studies at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
View PDF
Fate Therapeutics
May 7, 2015 - Fate Therapeutics Reports First Quarter 2015 Financial Results
View PDF
Fate Therapeutics
May 6, 2015 - Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies
View PDF
Immune Design
March 31, 2015 - Immune Design Announces Postivie Topline Data From Three Phase 1 Clinical Trials of Immuno-Oncology Agents
View PDF
Immune Design
March 31, 2015 - Immune Design Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update
View PDF
Immune Design
March 26, 2015 - Immune Design Announces Treatment of Patients With CMB305 Investigational Immuno-Oncology Agent
View PDF
Fate Therapeutics
March 12, 2015 - Fate Therapeutics Reports Year-End 2014 Financial Results
View PDF
Immune Design
February 11, 2015 - Immune Design Announces First Patients Dosed in Phase 1 Clinical Trial of G100 Investigational Immuno-Oncology Agent
View PDF
Proteostasis Therapeutics
February 4, 2015 - Proteostasis Therapeutics Announces a New Class of Agents for Cystic Fibrosis Called CFTR Amplifiers and Selects PTI130 as a Development Candidate
View PDF
Lysosomal Therapeutics
February 3, 2015 - Lysosomal Therapeutics Inc. Raises $20 Million in Series A Financing
View PDF
Ultragenyx Pharmaceutical
January 12, 2015 - Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy
View PDF
Fate Therapeutics
January 12, 2015 - Fate Therapeutics Announces Key 2015 Objectives for the Advancement of Programmed Cellular Therapeutics Pipeline
View PDF
Ultragenyx Pharmaceutical
January 7, 2015 - Ultragenyx Announces License of Intellectual Property Related to the Treatment of Huntington's Disease With Triheptanoin
View PDF
2014
Fate Therapeutics
December 18, 2014 - Fate Therapeutics Announces Iterim Data From Ongoing Phase 2 PUMA Study
View PDF
Ultragenyx Pharmaceutical
December 15, 2014 - Ultragenyx Announces Initiation of Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7
View PDF
Proteostasis Therapeutics
December 3, 2014 - Proteostasis Therapeutics Announces Appointment of Dr. Po-Shun Lee as Vice President of Clinical Development
View PDF
Immune Design
November 12, 2014 - Immune Design Reports Third Quarter 2014 Financial Results and Provides Corporate Update
View PDF
Fate Therapeutics
November 11, 2014 - Fate Therapeutics Reports Third Quarter 2014 Financial Results
View PDF
Ultragenyx Pharmaceutical
November 10, 2014 - Ultragenyx Reports Third Quarter 2014 Financial Results and Corporate Update
View PDF
Proteostasis Therapeutics
November 6, 2014 - Proteostasis Therapeutics Announces Scientific Publication in Cell Reports
View PDF
Proteostasis Therapeutics
November 4, 2014 - Proteostasis Therapeutics and Astellas Announce Collaboration for Research, Development and Commercialization of Therapies Modulating the Unfolded Protein Response
View PDF
Unum Therapeutics
October 21, 2014 - Fidelity Biosciences and Atlas Venture Lead $12 Million Series A Funding to Launch Unum Therapeutics, a New Cellular Immunotherapy Company
View PDF
Proteostasis Therapeutics
October 20, 2014 - Proteostasis Therapeutics Announces Appointments of Cystic Fibrosis Experts to Inaugural Clinical Advisory Board
View PDF
Immune Design
October 16, 2014 - Sanofi Pasteur and Immune Design Enter Broad Collaboration for the Development of a Herpes Simplex Virus Therapy
View PDF
Ultragenyx Pharmaceutical
October 13, 2014 - Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society
View PDF
Ultragenyx Pharmaceutical
September 15, 2014 - Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 Study of KRN23 in Adult Patients with X-Linked Hypophosphatemia
View PDF
Ultragenyx Pharmaceutical
September 3, 2014 - Ultragenyx Announces Positive Interim Data From Phase 1/2 Study of Recombinant Human Beta-Glucruronidase in Mucopolysaccharidosis 7
View PDF
KaloBios
August 14, 2014 - Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer Therapy
View PDF
Fate Therapeutics
August 12, 2014 - Fate Therapeutics Reports Second Quarter 2014 Financial Results
View PDF
Ultragenyx Pharmaceutical
August 11, 2014 - Ultragenyx Reports Second Quarter 2014 Financial Results and Corporate Update
View PDF
Immune Design
August 7, 2014 - Sanofi Licenses Immune Design's GLAAS Platform to Explore Novel Approach to Treat Food Allergy
View PDF
Ultragenyx Pharmaceutical
August 5, 2014 - Ultragenyx Announces License of Intellectual Property for the Treatment of Epilepsy and Other Seizure-Related Disorders With Triheptanoin
View PDF
Fate Therapeutics
July 31, 2014 - Fate Therapeutics Secures Up to $20 Million in Debt Financing
View PDF
Proteostasis Therapeutics
July 30, 2014 - Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec
View PDF
Fate Therapeutics
July 29, 2014 - Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders
View PDF
Ultragenyx Pharmaceutical
July 14, 2014 - Ultragenyx Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
View PDF
Ultragenyx Pharmaceutical
July 9, 2014 - Ultragenyx Announces Pricing of Public Offering of Common Stock
View PDF
Ultragenyx Pharmaceutical
July 1, 2014 - Ultragenyx Announces Initiation of a Phase 2 Study of KN23 for Pediatric X-Linked Hypophosphatemia in the US and EU
View PDF
Fate Therapeutics
June 30, 2014 - Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders
View PDF
Ultragenyx Pharmaceuticals
June 24, 2014 - Ultragenyx Announces Results From Phase 1/2 Study of KRN23 in X-linked Hypophosphatemia in Adults
View PDF
Fate Therapeutics
June 5, 2014 - Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo
View PDF
Immune Design
June 5, 2014 - Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of LV305 Immuno-Oncology Agent
View PDF
Edimer Pharmaceuticals
May 28, 2014 - Edimer Pharmaceuticals' EDI200 Expands to Higher Dose Cohort in Phase 2 Trial Following Positive Review of Safety Data
View PDF
Immune Design
May 27, 2014 - Immune Design's GLAAS Discovery Platform Used in MEDI7510 Phase 1 Trial for Respiratory Syncytial Virus
View PDF
Fate Therapeutics
May 13, 2014 - Fate Therapeutics Reports First Quarter 2014 Financial Results
View PDF
Lysosomal Therapeutics
May 12, 2014 - Lysosomal Therapeutics Inc. Receives $4.8 Million in Seed Funding
View PDF
Ultragenyx Pharmaceutical
May 12, 2014 - Ultragenyx Reports First Quarter 2014 Financial Results and Corporate Update
View PDF
Ultragenyx Pharmaceutical
April 30, 2014 - Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting
View PDF
Fate Therapeutics
April 23, 2014 - Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients
View PDF
Fate Therapeutics
April 10, 2014 - Fate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics
View PDF
MacroGenics
April 6, 2014 - MacroGenics Presents Pre-Clinical Data Demonstrating Potent Activity with Colorectal Cancer Product Candidate MGD007 at the AACR Annual Meeting
View PDF
Edimer Pharmaceuticals
April 1, 2014 - Edimer Pharmaceuticals Presents Update on Phase 2 Clinical Trial of ED1200 at International Gathering of Ectodermal Dysplasia Patient Foundations
View PDF
Ultragenyx Pharmaceutical
March 27, 2014 - Ultragenyx Announces Preliminary Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7
View PDF
Ultragenyx Pharmaceutical
March 24, 2014 - Ultragenyx Reports Fourth Quarter and Full Year 2013 Financial Results
View PDF
MacroGenics
March 20, 2014 - MacroGenics Provides Update on Corporate Progress and 2013 Financial Results
View PDF
Immune Design
March 18, 2014 - Immune Design Appoints Franklin M. Berger to Board of Directors
View PDF
Fate Therapeutics
March 17, 2014 - Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
View PDF
Fate Therapeutics
March 12, 2014 - Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies Type-1 Deficiency Syndrome
View PDF
Ultragenyx Pharmaceutical
March 11, 2014 - Ultragenyx Announces First Patient Enrolled in Phase 2 Study of Triheptanoin in Glucose Transporter Type-1 Deficiency Syndrome
View PDF
Fate Therapeutics
March 6, 2014 - Fate Therapeutics Announces Publication of Its Proprietary Stem Cell Modulation Platform for Developing iPSC-Based Regenerative Therapeutics
View PDF
Immune Design
February 27, 2014 - Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of ID-G305 Cancer Immunotherapy Agent
View PDF
Fate Therapeutics
February 26, 2014 - Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase 1b Study of PROHEMA(R)
View PDF
Ultragenyx Pharmaceutical
February 11, 2014 - Ultragenyx Announces Initiation of Phase 2 Study for Patients with Long-Chain Fatty Acid Oxidation Disorders
View PDF
KaloBios
February 11, 2014 - KaloBios Initiates Phase 2 Expansion Portion of Study of KB004 in Hematologic Malignancies
View PDF
Ultragenyx Pharmaceutical
February 6, 2014 - Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors
View PDF
Ultragenyx Pharmaceutical
January 30, 2014 - Ultragenyx Announces Pricing of Initial Public Offering
View PDF
Immune Design
January 27, 2014 - Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of ID-G100, an Investigational Immuno-Oncology Agent
View PDF
2013
Ultragenyx
December 20, 2013 - Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy
View PDF
December 4, 2013 - Ultragenyx Announces Initiation of Phase 1/2 Study of Recombinant Human Beta-Glucuronidase (rhGUS) in Mucopolysaccharidosis Type 7 (MPS 7)
View PDF
Ultragenyx
December 20, 2013 - Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy
View PDF
December 4, 2013 - Ultragenyx Announces Initiation of Phase 1/2 Study of Recombinant Human Beta-Glucuronidase (rhGUS) in Mucopolysaccharidosis Type 7 (MPS 7)
View PDF
bluebird bio
December 2, 2013 - bluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia
View PDF
KaloBios
October 30, 2013 - U.S. FDA Grants Orphan Drug Designation for KaloBios' KB001 - A in Treatment of Cystic Fibrosis Patients
View PDF
Proteostasis Therapeutics
October 18, 2013 - Proteostasis Therapeutics Presents Promising Preclinical Data at the 27th Annual North American Cystic Fibrosis Conference
View PDF
Edimer
October 8, 2013 - Edimer Initiates Phase 2 Trial of EDI200 in XLHED-Affected Male Newborns
View PDF
Fate Therapeutics
October 4, 2013 - Fate Therapeutics Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares
View PDF
KaloBios
September 26, 2013 - KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
View PDF
GlycoMimetics
September 13, 2013 - GlycoMimetics Announces EMA’s Granting of Orphan Drug Status in European Union for GMI-1070 in Sickle Cell Disease
View PDF
Edimer
July 30, 2013 - Edimer Secures $18M Series B Financing Led by New Enterprise Associates
View PDF
bluebird bio
June 24, 2013 - bluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option
View PDF
KaloBios
April 23, 2013 - U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios' Novel Biologic Candidate for Pseudomonas aeruginosa
View PDF
Fate Therapeutics
April 22, 2013 - Fate Therapeutics Presents Efficacy Data for WNT7a-Analog Program at Muscular Dystrophy Association 2013 Scientific Conference
View PDF
GlycoMimetics
April 16, 2013 - GlycoMimetics Announces Top Line Results from Phase 2 Trial with GMI-1070 in Sickle Cell Disease
View PDF
Kahr Medical
February 4, 2013 - KAHR Medical Granted U.S. Patent Approval for One of its Lead Products in Development, KAHR-101
View PDF
2012
Ultragenyx
December 19, 2012 - Ultragenyx Raises $75 Million in Oversubscribed Crossover Financing
View PDF